Aberrant MAP6 function may contribute to tau-independent cytoskeletal defects in neurodegeneration, and stabilizing MAP6-microtubule interactions pharmacologically could compensate for Tau pathology
Prediction: Small molecules enhancing MAP6-microtubule binding will ameliorate cytoskeletal defects in tau knockout neurons and improve neuronal survival in amyloid toxicity models
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["MAPT/Tau Occupancy Dynamic Microtubule Binding"]
B["MAP6 Occupancy Cold-Stable Domain Support"]
C["Shared Microtubule Lattice Domain Allocation Competition"]
D["GSK3B/CRMP2 Cue Integration Plasticity Signaling"]
E["Axonal Remodeling Balance Stable vs Labile Segments"]
F["Transport and Branching Adaptive Circuit Plasticity"]
G["Tau-MAP6 Imbalance Rigid or Unstable Cytoskeleton"]
A --> C
B --> C
C --> D
D --> E
E --> F
G -.->|"disrupts"| C
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#81c784,color:#81c784
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for MAP6 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
8 citations7 with PMID2 mediumValidation: 0%6 supporting / 2 opposing
✓For(6)
No supporting evidence
2
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
1
3
MECH 4CLIN 1GENE 3EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Tau/MAP6 antagonism is shown in neuronal developme…
Aberrant MAP6 function may contribute to tau-independent cytoskeletal defects in neurodegeneration, and stabil…▼
Aberrant MAP6 function may contribute to tau-independent cytoskeletal defects in neurodegeneration, and stabilizing MAP6-microtubule interactions pharmacologically could compensate for Tau pathology
Beyond Neuronal Microtubule Stabilization: MAP6 and CRMPS, Two Converging Stories.
Tau/MAP6 antagonism is shown in neuronal development models, but this does not establish that the same balance…MEDIUM▼
Tau/MAP6 antagonism is shown in neuronal development models, but this does not establish that the same balance drives adult neurodegeneration progression or treatment response.
A microtubule-stabilizing peptide strategy failed to show clinical benefit in progressive supranuclear palsy, …MEDIUM▼
A microtubule-stabilizing peptide strategy failed to show clinical benefit in progressive supranuclear palsy, cautioning against simple cytoskeletal-stabilization translation in tauopathy.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF primary cortical neurons from tau knockout mice are treated with a small molecule that enhances MAP6-microtubule binding (e.g., MS-12 or similar compound at 10 μM for 7 days), THEN acetylated α-tubulin levels will increase by at least 40% and neuronal viability will improve by at least 30% compared to vehicle-treated tau knockout neurons within 2 weeks of treatment.
Falsified by: Acetylated α-tubulin levels fail to increase significantly (p>0.05) or neuronal viability shows no improvement (<10% change) or decreases in MAP6-treated tau knockout neurons compared to vehicle control
Method: Primary cortical neuron culture from Tau knockout mice (B6;129-Mapt<tm1Led>/J or similar), treated with MAP6-binding enhancer or DMSO vehicle for 7 days, with immunoblotting for acetylated tubulin and microtubule co-sedimentation assays
IF 5xFAD amyloid transgenic mice (8 months old) are administered a MAP6 stabilizer (intraperitoneal injection at 20 mg/kg daily for 8 weeks), THEN spatial memory performance on the Morris water maze will improve by at least 25% (reduced escape latency) and cortical neuron survival will increase by at least 20% compared to vehicle-treated 5xFAD mice within 10 weeks.
pendingconf: 0.55
Expected outcome: Morris water maze escape latency: ≥25% reduction; Cortical neuron count (NeuN+ cells): ≥20% increase; Insoluble amyloid load: ≤10% change (to confirm direct cytoskeletal effect independent of amyloid clearance)
Falsified by: No significant improvement in spatial memory (escape latency reduction <15% or p>0.05), no increase in cortical neuronal survival, or behavioral improvement is accompanied by reduced amyloid load suggesting off-target effects
Method: 8-month-old male 5xFAD transgenic mice (B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax), randomized to MAP6 stabilizer (n=12) or vehicle (n=12) groups, 8-week treatment with weekly body weight monitoring, followed by Morris water maze testing and stereological neuron counting
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
Predicted Protein Structure
🔮
MAP6 — AlphaFold Prediction Q96JE9Click to expand 3D viewer
AI-predicted structure from AlphaFold | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click